Olema Pharmaceuticals
Develops oral therapies for breast cancer and other endocrine-driven tumors.
$10.50
After-hours close+0.22 (+2.14%)
At close$10.28(−4.73%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.60 | — | — |
| Aug 2026 | −$0.55 | −$0.61 | −10.6% |
| May 2026 | −$0.52 | −$0.52 | 0.0% |
| Mar 2026 | −$0.51 | −$0.50 | +2.0% |
| Nov 2025 | −$0.44 | −$0.49 | −11.4% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Sep 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | −$0.60 | — | — | $1.3M | — | — |
| Aug 10, 2026 | −$0.55 | −$0.61 | −10.6% | — | — | — |
| May 12, 2026 | −$0.52 | −$0.52 | 0.0% | — | — | — |
| Mar 16, 2026 | −$0.51 | −$0.50 | +2.0% | — | — | — |
| Nov 10, 2025 | −$0.44 | −$0.49 | −11.4% | — | — | — |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Aug 11, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 18, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 8, 2024 | ||||||
| Mar 11, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 9, 2023 | ||||||
| Mar 9, 2023 | ||||||
| Nov 8, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 9, 2022 | ||||||
| Feb 28, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 10, 2021 | ||||||
| May 11, 2021 | ||||||
| Mar 17, 2021 | ||||||
| Nov 19, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||